research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

Altered expression of histone deacetylases (HDACs) is a common feature in several human malignancies and may represent an interesting target for cancer treatment, including haematological malignancies. We evaluated the mRNA gene expression profile of 12 HDAC genes by quantitative real‐time polymerase chain reaction in 94 consecutive childhood acute lymphoblastic leukaemia (ALL) samples and its association with clinical/biological features and survival. ALL samples showed higher expression levels of HDAC2, HDAC3, HDAC8, HDAC6 and HDAC7 when compared to normal bone marrow samples. HDAC1 and HDAC4 showed high expression in T‐ALL and HDAC5 was highly expressed in B‐lineage ALL. Higher than median expression levels of HDAC3 were associated with a significantly lower 5‐year event‐free survival (EFS) in the overall group of patients (P = 0·03) and in T‐ALL patients (P = 0·01). HDAC7 and HADC9 expression levels higher than median were associated with a lower 5‐year EFS in the overall group (P = 0·04 and P = 0·003, respectively) and in B‐lineage CD10‐positive patients (P = 0·009 and P = 0·005, respectively). Our data suggest that higher expression of HDAC7 and HDAC9 is associated with poor prognosis in childhood ALL and could be promising therapeutic targets for the treatment of refractory childhood ALL.

[1]  C. Scrideli,et al.  Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Scrideli,et al.  mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death , 2009, Pediatric blood & cancer.

[3]  Wayne W. Hancock,et al.  Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells , 2009, Nature Reviews Drug Discovery.

[4]  J. Byrd,et al.  Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia , 2009, British journal of haematology.

[5]  R. Orlowski,et al.  Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors , 2009, British journal of haematology.

[6]  M. Tian,et al.  NF-kappaB family of transcription factor facilitates gene conversion in chicken B cells. , 2009, Molecular immunology.

[7]  Xiao Sun,et al.  Mechanism-anchored profiling derived from epigenetic networks predicts outcome in acute lymphoblastic leukemia , 2009, BMC Bioinformatics.

[8]  W. Weichert.  HDAC expression and clinical prognosis in human malignancies. , 2009, Cancer letters.

[9]  C. Scrideli,et al.  A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups , 2009, Haematologica.

[10]  O. Witt,et al.  HDAC family: What are the cancer relevant targets? , 2009, Cancer letters.

[11]  L. Altucci,et al.  Epigenetic therapies in haematological malignancies: searching for true targets. , 2009, European journal of cancer.

[12]  I. Christensen,et al.  Histone deacetylase 1, 2, 6 and acetylated histone H4 in B‐ and T‐cell lymphomas , 2009, Histopathology.

[13]  G. Schwartsmann,et al.  Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. , 2009, Leukemia research.

[14]  W. Weichert,et al.  Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. , 2008, Neoplasia.

[15]  I. Christensen,et al.  Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma , 2008, Histopathology.

[16]  C. Scrideli,et al.  Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas , 2008, BMC Cancer.

[17]  M. Minden,et al.  Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. , 2008, Blood.

[18]  D. Lombardo,et al.  High Histone Deacetylase 7 (HDAC7) Expression Is Significantly Associated with Adenocarcinomas of the Pancreas , 2008, Annals of Surgical Oncology.

[19]  W. Weichert,et al.  Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo , 2008, Clinical Cancer Research.

[20]  Carsten Denkert,et al.  Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. , 2008, The Lancet. Oncology.

[21]  P. Pandolfi,et al.  Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes , 2008, Clinical Cancer Research.

[22]  T. Yamagata,et al.  Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera , 2008, Cancer science.

[23]  W. Weichert,et al.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy , 2008, British Journal of Cancer.

[24]  Richard Pazdur,et al.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. , 2007, The oncologist.

[25]  Y. Oda,et al.  Expression profile of class I histone deacetylases in human cancer tissues. , 2007, Oncology reports.

[26]  E. Seto,et al.  Histone deacetylases and cancer , 2007, Oncogene.

[27]  J. Wong,et al.  HDAC3: taking the SMRT-N-CoRrect road to repression , 2007, Oncogene.

[28]  T. Kuzel,et al.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Gronemeyer,et al.  HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. , 2007, The international journal of biochemistry & cell biology.

[30]  Manel Esteller,et al.  The role of histone deacetylases (HDACs) in human cancer , 2007, Molecular oncology.

[31]  W. Ahn,et al.  Gene expression profiles in squamous cell cervical carcinoma using array-based comparative genomic hybridization analysis , 2006, International Journal of Gynecologic Cancer.

[32]  Michele Pallaoro,et al.  HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.

[33]  E. Lander,et al.  The Mammalian Epigenome , 2007, Cell.

[34]  Mark A. Brown,et al.  Epigenetic aberrations and cancer , 2006, Molecular Cancer.

[35]  Q. Lu,et al.  Epigenetics, disease, and therapeutic interventions , 2006, Ageing Research Reviews.

[36]  Robin Holliday,et al.  Epigenetics: A Historical Overview , 2006, Epigenetics.

[37]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[38]  E. Olson,et al.  Essential Role for Protein Kinase D Family Kinases in the Regulation of Class II Histone Deacetylases in B Lymphocytes , 2006, Molecular and Cellular Biology.

[39]  Y. Bang,et al.  Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.

[40]  A. Sparreboom,et al.  Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review , 2005, Molecular Pharmacology.

[41]  C. Bradbury,et al.  Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors , 2005, Leukemia.

[42]  H. M. Beier,et al.  Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis , 2005, Breast Cancer Research and Treatment.

[43]  M. Jung,et al.  Cytoplasmic Sequestration of HDAC7 from Mitochondrial and Nuclear Compartments upon Initiation of Apoptosis* , 2004, Journal of Biological Chemistry.

[44]  Y. Yatabe,et al.  Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients , 2004, International journal of cancer.

[45]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[46]  H. Kato,et al.  Histone Deacetylase 7 Associates with Hypoxia-inducible Factor 1α and Increases Transcriptional Activity* , 2004, Journal of Biological Chemistry.

[47]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[48]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[49]  Lyn Healy,et al.  The Histone Deacetylase 9 Gene Encodes Multiple Protein Isoforms* , 2003, The Journal of Biological Chemistry.

[50]  F. Dequiedt,et al.  Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.

[51]  Dong Hoon Kim,et al.  Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. , 2003, Journal of biochemistry and molecular biology.

[52]  J. Licht,et al.  Histone deacetylases as therapeutic targets in hematologic malignancies. , 2002, Current opinion in hematology.

[53]  H. Gruffat,et al.  MEF2‐mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling , 2002, EMBO reports.

[54]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[55]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[56]  Jun O. Liu,et al.  Deletion of Calcineurin and Myocyte Enhancer Factor 2 (MEF2) Binding Domain of Cabin1 Results in Enhanced Cytokine Gene Expression in T Cells , 2001, The Journal of experimental medicine.

[57]  Richard A. Rifkind,et al.  Cloning and characterization of a histone deacetylase, HDAC9 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Jun O. Liu,et al.  Integration of calcineurin and MEF2 signals by the coactivator p300 during T‐cell apoptosis , 2000, The EMBO journal.

[59]  W. D. Cress,et al.  Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.

[60]  H. Youn,et al.  Cabin1 represses MEF2-dependent Nur77 expression and T cell apoptosis by controlling association of histone deacetylases and acetylases with MEF2. , 2000, Immunity.

[61]  H. Youn,et al.  Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2. , 1999, Science.

[62]  E. Satyaraj,et al.  Mef2 Proteins, Required for Muscle Differentiation, Bind an Essential Site in the Ig λ Enhancer , 1998, The Journal of Immunology.

[63]  M. Koshland,et al.  Myocyte Enhancer Factor-related B-MEF2 Is Developmentally Expressed in B Cells and Regulates the Immunoglobulin J Chain Promoter* , 1998, The Journal of Biological Chemistry.

[64]  G. Lyons,et al.  Characterization of myocyte enhancer factor 2 (MEF2) expression in B and T cells: MEF2C is a B cell-restricted transcription factor in lymphocytes. , 1998, Molecular immunology.

[65]  Marja,et al.  Phase II study of the histone deacetylase inhibitor MGCD 0103 in patients with previously treated chronic lymphocytic leukaemia , 2009 .

[66]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[67]  J. Herman,et al.  The fundamental role of epigenetics in hematopoietic malignancies. , 2006, Blood reviews.

[68]  H. Koeffler,et al.  Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. , 2005, Experimental hematology.

[69]  P. Atadja,et al.  Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. , 2004, Haematologica.

[70]  E. Satyaraj,et al.  Mef2 proteins, required for muscle differentiation, bind an essential site in the Ig lambda enhancer. , 1998, Journal of immunology.